On Unicorns and Prescription Prices

On Unicorns and Prescription Prices
AP Photo/Sue Ogrocki, File

Since taking the Oath of Office just 16 months ago, President Trump's tenure as Chief Executive has been marked by notable successes — such as tax reform — and partisan controversies, such as alleged Russian collusion. What's remarkable about the president's brief tenure isn't so much that there have been successes or controversies. This, of course, is true of any new administration. What's remarkable is the unprecedented partisanship and division. There is no middle ground on issues where Left and Right might agree to disagree. Politics today is a blood sport: It's not enough to win the argument; you must destroy your political enemy.

Taxes, the environment, foreign policy, judges, immigration, entitlement reform, health care — there are fewer and fewer issues where both Republicans and Democrats can come together to work out policy solutions. Virtually the only thing everyone agrees upon is that drug prices are too high. Indeed, high drug prices just might be Washington's last “policy unicorn.” It's the mystical policy area where Senator Chuck Schumer (D-NY) and President Trump might agree.



Comment
Show comments Hide Comments


Related Articles